A Phase 1a/1b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PY159 as a Single Agent and In Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
Details
Age
Adult
Eligibility
patients enrolled to Part B must express TREM-1 by IHC.
Type of Study
Treatment
Locations
University of Colorado Hospital
Principal Investigator
Erin Schenk, MD, PhD
Study ID
Protocol Number: 20-2818
More information available at ClinicalTrials.gov: NCT04682431
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers